Meyahealth
HomeGeneticsGeneMFSD8 gene
Back to Gene
MFSD8 gene
Reviewed by Medicinsk Expert•Last updated: 2026-10-22•Gene

MFSD8 gene

The MFSD8 gene provides instructions for a protein located in lysosomes, though its specific function and the molecules it transports remain unknown.

Normal Function

The MFSD8 gene provides instructions for making a protein whose specific function is unknown. The MFSD8 protein is embedded in the membrane of lysosomes, which are cell compartments that digest and recycle different types of molecules. It belongs to the major facilitator superfamily of secondary active transporter proteins, which move molecules within a cell or in and out of cells. It is likely that MFSD8 transports molecules across the lysosomal membrane, but the specific molecules have not yet been identified.

Health Conditions Related to Genetic Changes

CLN7 disease

At least 30 mutations in the MFSD8 gene have been found to cause CLN7 disease. This condition typically begins in early childhood and involves a decline in mental and motor skills.

  • Symptoms: Developmental regression, recurrent seizures (epilepsy), muscle twitches (myoclonus), difficulty coordinating movements (ataxia), speech impairment, and vision loss.
  • Prognosis: Individuals with CLN7 disease typically do not survive past their teens.
  • Mechanism: Mutations likely lead to a protein with altered structure or function. The disease is characterized by the accumulation of proteins and other substances in lysosomes. Nerve cells are particularly vulnerable to these accumulations, which can lead to cell damage and death, resulting in the gradual loss of nerve cells in certain parts of the brain.

Other Names for This Gene

  • ceroid-lipofuscinosis neuronal protein 7
  • CLN7
  • major facilitator superfamily domain-containing protein 8
  • MFSD8_HUMAN
  • MGC33302

Frequently Asked Questions

coordinated team that includes a pediatric neurologist, ophthalmologist, physiotherapist, speech therapist, and genetic counselor is essential. Optimizing antiepileptic medication, providing adaptive equipment for mobility, using low‑vision aids, and offering behavioral support can slow functional decline and maintain independence for as long as possible. Regular cardiac and respiratory monitoring is also advised because secondary complications may arise.
The first clues often appear between ages 2–6 and include a noticeable loss of previously acquired motor or language skills (developmental regression), new‑onset seizures or myoclonic jerks, difficulty with balance (ataxia), and early visual problems such as night‑blindness or loss of peripheral vision. When two or more of these symptoms emerge, clinicians usually order neuroimaging and genetic testing.
t present, treatment is largely supportive—seizure control, physical therapy, and vision aids. However, several experimental approaches are under investigation, including adeno‑associated virus (AAV) gene‑replacement therapy and small‑molecule chaperones aimed at improving lysosomal function. Families should consult a specialized NCL center or clinicaltrials.gov for enrollment criteria in ongoing trials.
definitive diagnosis is made by sequencing the MFSD8 gene to identify pathogenic variants. The test can be performed on peripheral blood DNA, but saliva or buccal swab samples are also acceptable if blood draw is difficult. Some laboratories also offer targeted panels for neuronal ceroid lipofuscinoses that include MFSD8.
Source: MedlinePlus, National Library of Medicine

MedlinePlus brings together authoritative health information from the National Library of Medicine (NLM), the National Institutes of Health (NIH), and other government agencies and health-related organizations.

Meyahealth

Ⓒ 2026. All rights reserved by MEYA

About UsTerms & PolicyFAQ